关于上海伟测半导体科技股份有限公司 向不特定对象发行可转换公司债券申请文件的 审核问询函中有关财务事项的说明 目 录 | 一、关于融资规模和效益测算…………………………………第 | 1—21 | 页 | | --- | --- | --- | | 二、关于经营业绩………………………………………………第 | 21—38 | 页 | | 三、关于应收账款………………………………………………第 | 38—41 | 页 | | 四、关于固定资产和在建工程…………………………………第 | 41—46 | 页 | | 五、关于财务性投资……………………………………………第 | 46—53 | 页 | | 六、关于其他……………………………………………………第 | 53—55 | 页 | 关于上海伟测半导体科技股份有限公司 向不特定对象发行可转换公司债券申请文件的 审核问询函中有关财务事项的说明 天健函〔2024〕6-78号 上海证券交易所： 由平安证券股份有限公司转来的《关于上海伟测半导体科技股份有限公司向 不特定对象发行可转换公司债券申请文件的审核问询函》（上证科审（再融资） 〔2024〕90 号，以下简称审核问询函） ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a record high revenue of 740 million yuan in Q3 2024, representing a year-over-year increase of 43.62%. The net profit attributable to shareholders was 62 million yuan, down 30.81% year-over-year [1] - High-end products significantly boosted the gross margin to 42.45%, with a quarter-over-quarter increase of 12.39 percentage points [1] - The company plans to issue convertible bonds to raise up to 1.175 billion yuan for expanding high-end testing capacity [1] Financial Performance Summary - Total revenue for 2023 was 737 million yuan, with a projected increase to 1,016 million yuan in 2024, reflecting a year-over-year growth rate of 37.9% [2] - The net profit for 2023 was 118 million yuan, expected to rise to 133 million yuan in 2024, with a year-over-year growth of 12.5% [2] - The gross margin is projected to improve from 39.0% in 2023 to 39.8% in 2024 [2] Market Data - As of October 25, 2024, the closing price was 63.23 yuan, with a market capitalization of 4,904 million yuan [3] - The stock has a price-to-earnings ratio of 61 and a price-to-book ratio of 2.8 [3][4] Earnings Forecast - The company forecasts net profits of 133 million yuan, 210 million yuan, and 311 million yuan for 2024, 2025, and 2026 respectively, with corresponding price-to-earnings ratios of 54, 34, and 23 [2][7]

Investment Rating - The report upgrades the investment rating to "Buy" for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [11]. Core Views - The company's profitability has significantly recovered in Q3 2024, with a notable increase in the proportion of high-end testing services, which provides long-term growth momentum [2][4]. - The demand for high-end testing has increased due to the recovery in the semiconductor industry, particularly for high-performance chips such as CPUs, GPUs, and AI chips [2][4]. - The company is expanding its high-end testing capacity and increasing R&D investment to address the challenges in testing high-end chips, positioning itself as a key supplier in the domestic market [2][4]. Financial Performance Summary - Revenue for Q3 2024 reached 310 million yuan, a year-on-year increase of 52.47% and a quarter-on-quarter increase of 26.03% [1]. - The gross margin for Q3 2024 was 42.45%, up 3.08 percentage points year-on-year, while the net margin was 16.48%, up 7.21 percentage points year-on-year [2]. - The company reported a net profit of 51 million yuan in Q3 2024, a year-on-year increase of 171.09% and a quarter-on-quarter increase of 358.34% [1][2]. Revenue and Profit Forecast - The company forecasts revenues of 1.07 billion yuan for 2024, 1.3 billion yuan for 2025, and 1.59 billion yuan for 2026, with corresponding net profits of 130 million yuan, 235 million yuan, and 295 million yuan respectively [1][4]. - The expected EPS for 2024, 2025, and 2026 are 1.14 yuan, 2.07 yuan, and 2.59 yuan respectively [4][6]. Market Outlook - The integrated circuit testing market in mainland China is expected to continue growing at a double-digit rate, reaching 74 billion yuan by 2027 [4]. - The company is well-positioned to benefit from the high demand for high-end testing services and the ongoing domestic substitution process in the semiconductor industry [4].

卫星化学：前三季度净利润同比增长7.64% 财联社10月21日电，卫星化学发布2024年第三季度报告，前 三季度实现营业收入322.75亿元，同比增长0.71%；归属于上市公司股东的净利润36.93亿元，同比增长 7.64%；基本每股收益1.10元。 其中，第三季度实现营业收入128.75亿元，归属于上市公司股东的净利润16.37亿元。 查看公告原文 ...

财联社财经通讯社打开APP18:34:14【鹭燕医药：前三季度营收154.14亿元 净利润2.57亿元】财联社10 月21日电，鹭燕医药发布2024年第三季度报告，前三季度实现营收154.14亿元，同比增长4.32%；归属 于上市公司股东的净利润2.57亿元，同比下降1.77%；基本每股收益0.66元。 第三季度实现营收51.07亿元，同比增长7.51%；归属于上市公司股东的净利润6697.33万元，同比下降 8.21%。 鹭燕医药+0.24%A股公告速递查看公告原文财联社声明：文章内容仅供参考，不构成投资建议。 投资者据此操作，风险自担。 2024-10-21 18:34:1451520 阅读商务合作发送 ...

晶丰明源：筹划重大资产重组事项 股票明日起停牌 《科创板日报》21日讯，晶丰明源公告，公司正在 筹划以发行股份、发行定向可转换公司债券及支付现金方式购买四川易冲科技有限公司控制权，同时拟 募集配套资金。 经初步测算，本次交易预计构成重大资产重组，并构成关联交易。 本次交易前，公司与交易对方不存在关联关系。 本次交易不会导致公司实际控制人发生变更。 公司股票将于2024年10月22日开市起停牌，预计停牌时间不超过5个交易日。 查看公告原文 ...

创业板系列指数收涨，创业板200ETF易方达（159572）、创业板成长ETF易方达（159597）等产品受 市场关注 截至收盘，今日创业板中盘200指数上涨4.5%，创业板指数上涨0.7%，创业板成长指数上涨 0.6%。 ...

央行开展互换便利首次操作 中金公司达成首笔质押式回购交易 财联社10月21日电，中金公司于今日达 成了"证券、基金、保险公司互换便利"下的首笔质押式回购交易，质押券为2024年第一期互换便利央行 债券。 中金公司称，将继续落实中央部署，发挥稳市作用，全力支持宏观政策实施。 ...

华夏幸福最新200亿元"置换带"化债方案曝光 国资拟参与 财联社10月21日电，化债走过3个年头的华夏 幸福，近日拟在其《债务重组计划》中推出新的"置换带方案"。 该方案拟引入廊坊市属国企承接部分金融债权人的债务，作为条件，这些金融债权人须向廊坊市属国有 企业或其指定主体提供新增融资。 本次实施置换带的债务规模预计200亿元左右，最终以参与置换带的金融债权人和廊坊市属国有企业双 方确认的结果为准。 公司在方案中表示，该方案履行的效果，对参与置换带的债权人而言，存量债务由更具备清偿能力的廊 坊市属国有企业承接；对未参与置换带的债权人而言，包括"兑抵接"在内的公司债务金额整体实现压 降，现金兑付比例得到提高。 债权人可结合自身情况自愿选择是否参与《置换带方案》。 (证券时报) ...

人民同泰：第三季度净利润7081.25万元 同比下降18.79% 财联社10月21日电，人民同泰发布2024年第三 季度报告。 报告期内，公司实现营业收入26.93亿元，同比增长5.6%；归属于上市公司股东的净利润7081.25万元， 同比下降18.79%。 查看公告原文 ...